These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
281 related articles for article (PubMed ID: 22258374)
1. [Immunotherapy for metastatic prostate cancer: do we really need this?]. Heidenreich A Urologe A; 2012 Jan; 51(1):32-8. PubMed ID: 22258374 [TBL] [Abstract][Full Text] [Related]
3. Role of immunotherapy in castration-resistant prostate cancer (CRPC). Suárez C; Morales-Barrera R; Ramos V; Núñez I; Valverde C; Planas J; Morote J; Maldonado X; Carles J BJU Int; 2014 Mar; 113(3):367-75. PubMed ID: 23650874 [TBL] [Abstract][Full Text] [Related]
4. The evolving role of immunotherapy in prostate cancer. Gerritsen WR Ann Oncol; 2012 Sep; 23 Suppl 8():viii22-7. PubMed ID: 22918924 [TBL] [Abstract][Full Text] [Related]
5. EAU-ESTRO-SIOG Guidelines on Prostate Cancer. Part II: Treatment of Relapsing, Metastatic, and Castration-Resistant Prostate Cancer. Cornford P; Bellmunt J; Bolla M; Briers E; De Santis M; Gross T; Henry AM; Joniau S; Lam TB; Mason MD; van der Poel HG; van der Kwast TH; Rouvière O; Wiegel T; Mottet N Eur Urol; 2017 Apr; 71(4):630-642. PubMed ID: 27591931 [TBL] [Abstract][Full Text] [Related]
6. [How should hormone therapy for castration-resistant prostate cancer be continued?]. Spahn M; Krebs M Urologe A; 2012 Jan; 51(1):15-9. PubMed ID: 22258371 [TBL] [Abstract][Full Text] [Related]
7. Treating Patients with Metastatic Castration Resistant Prostate Cancer: A Comprehensive Review of Available Therapies. Crawford ED; Higano CS; Shore ND; Hussain M; Petrylak DP J Urol; 2015 Dec; 194(6):1537-47. PubMed ID: 26196735 [TBL] [Abstract][Full Text] [Related]
8. Integration of immunotherapy into the management of advanced prostate cancer. Kantoff P; Higano CS Urol Oncol; 2012; 30(5 Suppl):S41-7. PubMed ID: 23040162 [TBL] [Abstract][Full Text] [Related]
9. Novel therapeutics for the management of castration-resistant prostate cancer (CRPC). Lee DJ; Cha EK; Dubin JM; Beltran H; Chromecki TF; Fajkovic H; Scherr DS; Tagawa ST; Shariat SF BJU Int; 2012 Apr; 109(7):968-85. PubMed ID: 22035221 [TBL] [Abstract][Full Text] [Related]
10. Update on Systemic Prostate Cancer Therapies: Management of Metastatic Castration-resistant Prostate Cancer in the Era of Precision Oncology. Nuhn P; De Bono JS; Fizazi K; Freedland SJ; Grilli M; Kantoff PW; Sonpavde G; Sternberg CN; Yegnasubramanian S; Antonarakis ES Eur Urol; 2019 Jan; 75(1):88-99. PubMed ID: 29673712 [TBL] [Abstract][Full Text] [Related]
13. Combined immunotherapy with granulocyte-macrophage colony-stimulating factor-transduced allogeneic prostate cancer cells and ipilimumab in patients with metastatic castration-resistant prostate cancer: a phase 1 dose-escalation trial. van den Eertwegh AJ; Versluis J; van den Berg HP; Santegoets SJ; van Moorselaar RJ; van der Sluis TM; Gall HE; Harding TC; Jooss K; Lowy I; Pinedo HM; Scheper RJ; Stam AG; von Blomberg BM; de Gruijl TD; Hege K; Sacks N; Gerritsen WR Lancet Oncol; 2012 May; 13(5):509-17. PubMed ID: 22326922 [TBL] [Abstract][Full Text] [Related]
14. New therapeutics to treat castrate-resistant prostate cancer. Acar O; Esen T; Lack NA ScientificWorldJournal; 2013; 2013():379641. PubMed ID: 23781155 [TBL] [Abstract][Full Text] [Related]
15. [Role of chemotherapy in castration-resistant prostate cancer: are there new approaches?]. De Santis M; Bachner M Urologe A; 2012 Jan; 51(1):39-43. PubMed ID: 22258375 [TBL] [Abstract][Full Text] [Related]
16. Novel therapeutic strategies for metastatic prostate cancer in the post-docetaxel setting. Sartor O; Michels RM; Massard C; de Bono JS Oncologist; 2011; 16(11):1487-97. PubMed ID: 22048000 [TBL] [Abstract][Full Text] [Related]
17. Systemic therapy in men with metastatic castration-resistant prostate cancer: a systematic review. Loblaw DA; Walker-Dilks C; Winquist E; Hotte SJ; Clin Oncol (R Coll Radiol); 2013 Jul; 25(7):406-30. PubMed ID: 23587782 [TBL] [Abstract][Full Text] [Related]
18. Current status of immunological approaches for the treatment of prostate cancer. Drake CG; Antonarakis ES Curr Opin Urol; 2012 May; 22(3):197-202. PubMed ID: 22328018 [TBL] [Abstract][Full Text] [Related]